Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 10

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 10
---
 2024
to August 2, 2024, the Company sold a total of 135,568 shares in the ATM Offering for gross proceeds of $1,994,583.

Mission

Our
mission is to address the unmet medical need associated with infectious diseases through the development and commercialization of new
small molecule therapeutics, focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based
on prior clinical studies, in order to reduce cost, risk, and capitalize on existing research. We are seeking to expand Arakoda’s
use beyond malaria prevention and to demonstrate clinical benefit for other disease indications. We are further testing the viability
of another product (Celgosivir) to determine whether to advance it into further clinical development, and may seek to develop and license
other molecules in the future. Celgosivir is being considered for development as an antiviral product for a number of diseases.

Market
Opportunity

Malaria
Prevention

In
2018, the FDA approved Arakoda for malaria prevention in individuals 18 years and older. Arakoda entered the U.S. supply chain in the
third quarter of 2019, just prior to the COVID-19 pandemic. As the approved indication is for travel medicine, and international travel
was substantially impacted by the pandemic, we did not undertake any active marketing efforts for Arakoda. Following our financing in
January 2024, the Company hired a Chief Commercial Officer and commissioned IQVIA market data and a qualitative marketing demand study.
That research, recently completed, suggests that prescribing for malaria prevention therapies has returned to pre-pandemic levels, and
that the total U.S. market represents around 1.1 million prescriptions (one prescription per three weeks of travel). Based on consumer
and HCP demand research, the Company estimates that the accessible market for Arakoda represents about one third of this volume (about
330,000 prescriptions). Barriers to entry include low brand awareness in the prescriber community and the low cost of some of the generic
alternatives. In the second half of 2024 we will conduct a pilot commercialization study to confirm these barriers can be overcome (see
“Strategy”).

5

Treatment
and Prevention of Tick-Borne Disease (Babesiosis)

We
are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseload